Jing Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9450662/publications.pdf

Version: 2024-02-01

31 papers	2,303 citations	279487 23 h-index	433756 31 g-index
32 all docs	32 docs citations	32 times ranked	3490 citing authors

#	Article	IF	Citations
1	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nature Chemical Biology, 2022, 18, 821-830.	3.9	43
2	Inactive and active state structures template selective tools for the human 5-HT5A receptor. Nature Structural and Molecular Biology, 2022, 29, 677-687.	3.6	18
3	A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science Translational Medicine, 2021, 13, eabj1578.	5.8	67
4	Structure, function and pharmacology of human itch GPCRs. Nature, 2021, 600, 170-175.	13.7	101
5	Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. Journal of Medicinal Chemistry, 2020, 63, 1216-1232.	2.9	111
6	Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders. Journal of Medicinal Chemistry, 2020, 63, 14562-14575.	2.9	29
7	Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders. Journal of Medicinal Chemistry, 2020, 63, 9977-9989.	2.9	58
8	Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 5477-5487.	2.9	24
9	Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nature Neuroscience, 2020, 23, 1157-1167.	7.1	187
10	Designing Functionally Selective Noncatechol Dopamine D₁ Receptor Agonists with Potent In Vivo Antiparkinsonian Activity. ACS Chemical Neuroscience, 2019, 10, 4160-4182.	1.7	21
11	Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68). Journal of Medicinal Chemistry, 2019, 62, 7557-7574.	2.9	16
12	Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1). Journal of Medicinal Chemistry, 2019, 62, 8996-9007.	2.9	20
13	Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader. Journal of Medicinal Chemistry, 2019, 62, 10897-10911.	2.9	43
14	D₂ Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. Journal of Medicinal Chemistry, 2019, 62, 4755-4771.	2.9	15
15	A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nature Communications, 2019, 10, 19.	5.8	113
16	Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). European Journal of Medicinal Chemistry, 2018, 151, 304-314.	2.6	165
17	DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology and Translational Science, 2018, 1, 61-72.	2.5	143
18	Structural determinants of 5-HT2B receptor activation and biased agonism. Nature Structural and Molecular Biology, 2018, 25, 787-796.	3.6	116

#	Article	IF	Citations
19	Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase. Journal of Medicinal Chemistry, 2017, 60, 1876-1891.	2.9	54
20	In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nature Chemical Biology, 2017, 13, 529-536.	3.9	230
21	Structure-activity relationship studies of G9a-like protein (GLP) inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4414-4423.	1.4	24
22	Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6. Journal of Medicinal Chemistry, 2016, 59, 9124-9139.	2.9	64
23	Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 1044-1049.	1.3	19
24	A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. ACS Chemical Biology, 2016, 11, 772-781.	1.6	208
25	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo. Molecular Cancer Therapeutics, 2013, 12, 2367-2377.	1.9	53
26	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013, 123, 2257-2267.	3.9	124
27	Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Medicinal Chemistry Letters, 2012, 3, 129-134.	1.3	67
28	Synthesis and evaluation of 8,9-amido analogs of geldanamycin. Tetrahedron Letters, 2009, 50, 6705-6708.	0.7	10
29	Synthesis of polyhydroxylated ester analogs of the stilbene resveratrol using decarbonylative Heck couplings. Tetrahedron Letters, 2006, 47, 5811-5814.	0.7	39
30	Asymmetric Glycolate Aldol Reactions Using Cinchonium Phase-Transfer Catalysts. Organic Letters, 2005, 7, 3861-3864.	2.4	41
31	Synthesis of resveratrol using a direct decarbonylative Heck approach from resorcylic acid. Tetrahedron Letters, 2003, 44, 4819-4822.	0.7	79